BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Palmer J, Leeuwenkamp OR. Cost-effectiveness of lutetium (177Lu) oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden. World J Clin Cases 2020; 8(20): 4793-4806 [PMID: 33195647 DOI: 10.12998/wjcc.v8.i20.4793]
URL: https://www.wjgnet.com/1007-9327/full/v8/i20/4793.htm
Number Citing Articles
1
Ioana-Alexandra Soare, Oscar Leeuwenkamp, Louise Longworth. Estimation of Health-Related Utilities for 177Lu-DOTATATE in GEP-NET Patients Using Utilities Mapped from EORTC QLQ-C30 to EQ-5D-3L and QLU-C10D UtilitiesPharmacoEconomics - Open 2021; 5(4): 715 doi: 10.1007/s41669-021-00280-9
2
Tony Cox, Matthew O’Connell, Oscar Leeuwenkamp, Stefan Palimaka, Nicholas Reed. Real-world comparison of healthcare resource utilization and costs of [177Lu]Lu-DOTA-TATE in patients with progressive neuroendocrine tumors in England: a matched cohort analysis using data from the hospital episode statistics datasetCurrent Medical Research and Opinion 2022; 38(8): 1305 doi: 10.1080/03007995.2022.2065146
3
Dirk Mehrens, Kristina K.M. Kramer, Lena M. Unterrainer, Leonie Beyer, Peter Bartenstein, Matthias F. Froelich, Fabian Tollens, Jens Ricke, Johannes Rübenthaler, Nina-Sophie Schmidt-Hegemann, Annika Herlemann, Marcus Unterrainer, Wolfgang G. Kunz. Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate CancerJournal of the National Comprehensive Cancer Network 2023; 21(1): 43 doi: 10.6004/jnccn.2022.7070
4
Jessica Hooper, Nikie Jervis, Lucy Morgan, Vivienne Beckett, Philippa Hand, Kate Higgs, Alia Munir, Jenny Prinn, D Mark Pritchard, Debashis Sarker, Raj Srirajaskanthan, Catherine Bouvier Ellis. Neuroendocrine neoplasms: Consensus on a patient care pathwayJournal of Neuroendocrinology 2024;  doi: 10.1111/jne.13380